Nektar's proprietary Advanced Polymer Conjugate Technology platform allows for a custom approach that capitalizes on the properties of polymer medicinal chemistry and an understanding of both a drug's characteristics and the body's mechanisms.

Our scientists identify specific drug molecules, both large and small, that with customized chemical modification using uniquely-designed polymers can be enabled or made more efficacious. With our proprietary conjugate approaches, suboptimal drugs can be designed to dial in desired therapeutic properties and create an optimized and potentially superior therapeutic.

Read about our advanced polymer conjugate technology approaches »

Featured Publications on Nektar's Technology Platform 2008 Review Article in Journal of Pharmaceutical Sciences "The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics" Nektar Scientists Discuss Advanced Polymer Conjugate Technology Approaches in Pharmaceutical Technology Magazine Scientific and Medical Events Jan 27-31, 2009 American Academy of Pain Medicine (AAPM) 25th Annual Meeting Honolulu, HI Feb 27, 2009 ESMO 7th International Symposium on Advanced Ovarian Cancer Valencia, Spain

"When we design a new drug candidate, we bring together our knowledge of a drug with our understanding of medicinal polymer chemistry and the body's mechanisms. This allows us to turn a sub-optimal drug into a new chemical entity with the potential to be more efficacious and have more desirable characteristics." Timothy A. Riley, Ph.D. Senior Vice President, Global Research